“…Ferroelectrics and dielectric MgFe 2 O 4 @CuS NPs will convert the absorbed electromagnetic waves to heat energy through electromagnetic energy loss, which leads to a temperature increase of aqueous solution containing MgFe 2 O 4 @CuS NPs. 29 It is suggested that MgFe 2 O 4 @CuS NPs were suitable for localized hyperthermia to controlled-release drug and treatment of cancers. Figure 8 Frequency dependence of reflection loss with different thicknesses: ( A ) MgFe 2 O 4 NPs, ( B ) MgFe 2 O 4 @CuS NPs and ( C ) The electromagnetic wave thermal response of time-dependent temperature curve for the sodium chloride solution, MgFe 2 O 4 and MgFe 2 O 4 @CuS NPs dispersed in sodium chloride solution with electromagnetic wave irradiation.…”
Introduction
Cancer is a major health problem worldwide, and the most extensive treatment can be obtained by using chemotherapy in the clinic. However, due to the low selectivity of cancer cells, chemotherapy drugs produce a series of grievous side effects on normal cells.
Methods
In this research, we developed novel nanocarriers for magnetically targeted near-infrared (NIR) light-electromagnetic wave dual controlled drug delivery based on MgFe
2
O
4
@CuS nanoparticles (NPs) modified with aminopropyltriethoxysilane (APTES) in response to magnetic, NIR light, and electromagnetic wave irradiation. Synthesis and characterization of MgFe
2
O
4
@CuS-APTES NPs was carried out using X-ray diffraction measurements, scanning electron microscopy, transmission electron microscopy, photoluminescence emission spectra, UV-1800 spectrophotometer, N5230A vector network analyzer, MDS-6 microwave sample preparation system, and superconducting quantum interference device. In addition to that mentioned above, we also explored many other sides, such as the drug-loading, drug-controlled release efficiency, elect99omagnetic wave thermal effect and photo-thermal effect.
Results
The results showed that APTES-modified MgFe
2
O
4
@CuS NPs had 37% high drug-loading capacity and high electromagnetic wave thermal conversion ability and NIR-light thermal conversion ability. In addition, ibuprofen (IBU) release from the MgFe
2
O
4
@CuS-APTES-IBU depends on the electromagnetic wave (2.45 GHz) and 1060 nm NIR light irradiation. After five cycles, the drug-release percentage was 90% and 66% separately, and could be adjusted by the time and cycles times of electromagnetic wave and NIR light irritation. Electromagnetic wave irradiation compared with NIR light irradiation, has a higher drug release rate and better penetration. Therefore, choosing different stimulation methods according to the treatment needs of the disease, we can achieve accurate personalized treatment of the disease.
Discussion
Our findings indicate that multifunctional APTES modified MgFe
2
O
4
@CuS NPs could be used for the first time as a new drug carrier for “location-timing-quantification” drug release with magnetic targeting and dual control of NIR light-electromagnetic waves.
“…Ferroelectrics and dielectric MgFe 2 O 4 @CuS NPs will convert the absorbed electromagnetic waves to heat energy through electromagnetic energy loss, which leads to a temperature increase of aqueous solution containing MgFe 2 O 4 @CuS NPs. 29 It is suggested that MgFe 2 O 4 @CuS NPs were suitable for localized hyperthermia to controlled-release drug and treatment of cancers. Figure 8 Frequency dependence of reflection loss with different thicknesses: ( A ) MgFe 2 O 4 NPs, ( B ) MgFe 2 O 4 @CuS NPs and ( C ) The electromagnetic wave thermal response of time-dependent temperature curve for the sodium chloride solution, MgFe 2 O 4 and MgFe 2 O 4 @CuS NPs dispersed in sodium chloride solution with electromagnetic wave irradiation.…”
Introduction
Cancer is a major health problem worldwide, and the most extensive treatment can be obtained by using chemotherapy in the clinic. However, due to the low selectivity of cancer cells, chemotherapy drugs produce a series of grievous side effects on normal cells.
Methods
In this research, we developed novel nanocarriers for magnetically targeted near-infrared (NIR) light-electromagnetic wave dual controlled drug delivery based on MgFe
2
O
4
@CuS nanoparticles (NPs) modified with aminopropyltriethoxysilane (APTES) in response to magnetic, NIR light, and electromagnetic wave irradiation. Synthesis and characterization of MgFe
2
O
4
@CuS-APTES NPs was carried out using X-ray diffraction measurements, scanning electron microscopy, transmission electron microscopy, photoluminescence emission spectra, UV-1800 spectrophotometer, N5230A vector network analyzer, MDS-6 microwave sample preparation system, and superconducting quantum interference device. In addition to that mentioned above, we also explored many other sides, such as the drug-loading, drug-controlled release efficiency, elect99omagnetic wave thermal effect and photo-thermal effect.
Results
The results showed that APTES-modified MgFe
2
O
4
@CuS NPs had 37% high drug-loading capacity and high electromagnetic wave thermal conversion ability and NIR-light thermal conversion ability. In addition, ibuprofen (IBU) release from the MgFe
2
O
4
@CuS-APTES-IBU depends on the electromagnetic wave (2.45 GHz) and 1060 nm NIR light irradiation. After five cycles, the drug-release percentage was 90% and 66% separately, and could be adjusted by the time and cycles times of electromagnetic wave and NIR light irritation. Electromagnetic wave irradiation compared with NIR light irradiation, has a higher drug release rate and better penetration. Therefore, choosing different stimulation methods according to the treatment needs of the disease, we can achieve accurate personalized treatment of the disease.
Discussion
Our findings indicate that multifunctional APTES modified MgFe
2
O
4
@CuS NPs could be used for the first time as a new drug carrier for “location-timing-quantification” drug release with magnetic targeting and dual control of NIR light-electromagnetic waves.
“…Similar results have been found by previous research studies. 56,57 It is believed that the resonant frequency (f r ) follows the equation of f r = γH α /(2π), where γ refers to the gyromagnetic ratio, H α is the anisotropy field, which is highly sensitive to magnetic particle morphology and size as well as their interactions. 11 For the oriented A-F-Fe/MREF composites, a higher permeability was obtained and f r shows a slight shift to a lower frequency of 2.83 GHz, as indicted in Figure 6f.…”
A flaky Fe-based mangetorheological elastomer film (F-Fe/MREF) composite was developed through mixing micronsized flaky Fe particles into a silicone rubber (SR) matrix by compression molding and vulcanization. The 28 wt % F-Fe/MREF with a thickness of 4.3 mm displays dual resonance peaks with an optimal reflection loss (RL) value of −53.3 dB at 4.8 GHz and an effective frequency bandwidth (RL < −10 dB) reaches 6.0 GHz. Furthermore, anisotropic F-Fe/MREF obtained by assistance of an external magnetic field demonstrates an effective bandwidth of 12.5 GHz in one thickness. This is attributed to the synergistic contributions from magnetic loss and dielectric loss and good impedance matching along with promotion of multiple reflections and scatterings. Besides, an MR effect of 39.2% was obtained for anisotropy F-Fe/MREF because of interaction enhancement between F-Fe particles and the cross-linked matrix. These results suggest that the F-Fe/MREF composites could serve as a potential candidate toward applications of electromagnetic wave absorbing.
“…In addition, the permeability remains essentially unchanged, has no magnetic moment to result in very low permeability [33]. Therefore, little change in permeability occurs after Mg doping.…”
Section: Influence Of Mg or Sr Doping On The Absorption Properties Ofmentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
